ESMO 2023: Opdivo regimen boosts bladder cancer survival

23 October 2023

Bristol Myers Squibb (NYSE: BMY) has announced the first presentation of results from the Phase III CheckMate -901 trial involving Opdivo (nivolumab) at the 2023 European Society for Medical Oncology (ESMO) Congress.

Alongside cisplatin-based chemotherapy followed by Opdivo monotherapy, the immune checkpoint inhibitor demonstrated statistically-significant and clinically-meaningful improvements in the primary efficacy endpoints of overall survival (OS) and progression-free survival (PFS) as a first-line treatment for unresectable or metastatic urothelial carcinoma patients who are cisplatin-eligible.

With a median follow-up of approximately 33 months, treatment with Opdivo in combination with cisplatin-based chemotherapy reduced the risk of death by 22%, demonstrating a median OS of 21.7 months versus 18.9 months with chemotherapy alone.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK